Current Role of Immunotherapy in RCC

Toni K. Choueiri, MD, director of the Lank Center for Genitourinary Oncology, director of the Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine at Harvard Medical School, Dana-Farber Cancer Institute, discusses the current role of immunotherapy in the treatment of patients with renal cell carcinoma (RCC).

Over the last decade, a variety of cytokine, VEGF, and mTOR inhibitors have been available in RCC. Now, Choueiri says, immunotherapy is coming back in the form of checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4.